Influenza Vaccine Market, 2012 to 2023
Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains.
Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth influenza vaccine market.
Influenza Vaccines market has been segmented on the basis of vaccine type, strain type, formulation type, end user, and region
Based on vaccine type, Influenza Vaccines market segmented as follows:
Killed or Inactivated Vaccine
Live Vaccine
Based on strain type, Influenza Vaccines market segmented as follows:
Trivalent Influenza Vaccine
Quadrivaleant Influenza Vaccine
Based on formulation type, Influenza Vaccines market segmented as follows:
Injections
Nasal Sprays
Based on distribution channel, Influenza Vaccines market segmented as follows:
Government Immunization programmes
Non Governmental Organizations (NGOs)
Hospitals
Clinics
Players in influenza vaccine market focusing on developing effective vaccine i.e.quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance, in June 2016, Sanofi received a positive end of a procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance, in 2015, Sinovac Biotech Ltd. received the tender award from Beijing government to supply seasonal influenza vaccine.
Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and the Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. An occurrence of influenza infections high in developing countries than developed counters which make the market lucrative for players in developing countries. However, Influenza vaccine market in North America expected to witness significant growth owing U.S.’s yearly vaccination programme. In Europe influenza vaccine limited to the high-risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.
Some of the players in the influenza vaccines market include GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation to name a few. There are several influenza vaccine candidates in a late-stage clinical pipeline which are expected hit the market in the forecast period. For instance, in 2017 Daiichi Sankyo’s VN-100 and MEDI3250 influenza vaccine expected to get market approval in Japan.
In Jan 2016, CSL Limited acquired Novartis AG’s influenza vaccine business in Germany, as a part of global influenza vaccine
In June 2016, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has recommended not to use AstraZeneca’s FluMist Quadrivalent Influenza vaccine in any settings owing to lack of statistically significant effectiveness in children
Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth influenza vaccine market.
Influenza Vaccines market has been segmented on the basis of vaccine type, strain type, formulation type, end user, and region
Based on vaccine type, Influenza Vaccines market segmented as follows:
Killed or Inactivated Vaccine
Live Vaccine
Based on strain type, Influenza Vaccines market segmented as follows:
Trivalent Influenza Vaccine
Quadrivaleant Influenza Vaccine
Based on formulation type, Influenza Vaccines market segmented as follows:
Injections
Nasal Sprays
Based on distribution channel, Influenza Vaccines market segmented as follows:
Government Immunization programmes
Non Governmental Organizations (NGOs)
Hospitals
Clinics
Players in influenza vaccine market focusing on developing effective vaccine i.e.quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance, in June 2016, Sanofi received a positive end of a procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance, in 2015, Sinovac Biotech Ltd. received the tender award from Beijing government to supply seasonal influenza vaccine.
Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and the Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. An occurrence of influenza infections high in developing countries than developed counters which make the market lucrative for players in developing countries. However, Influenza vaccine market in North America expected to witness significant growth owing U.S.’s yearly vaccination programme. In Europe influenza vaccine limited to the high-risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.
Some of the players in the influenza vaccines market include GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation to name a few. There are several influenza vaccine candidates in a late-stage clinical pipeline which are expected hit the market in the forecast period. For instance, in 2017 Daiichi Sankyo’s VN-100 and MEDI3250 influenza vaccine expected to get market approval in Japan.
In Jan 2016, CSL Limited acquired Novartis AG’s influenza vaccine business in Germany, as a part of global influenza vaccine
In June 2016, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has recommended not to use AstraZeneca’s FluMist Quadrivalent Influenza vaccine in any settings owing to lack of statistically significant effectiveness in children
1. EXECUTIVESUMMARY
2. GLOBAL INFLUENZA VACCINES MARKET INTRODUCTION
2.1. Global Influenza Vaccines market – Taxonomy
2.2. Global Influenza Vaccines market –Definitions
2.2.1. Vaccine Type
2.2.2. Strain Type
2.2.3. Formulation Type
2.2.4. Distribution Channel
2.2.5. Region
3. GLOBAL INFLUENZA VACCINES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Influenza Vaccines market Dynamics – Factors Impact Analysis
3.6. Global Influenza Vaccines market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Influenza Vaccines market – Product Innovations
3.8. Competitor Landscape
4. GLOBAL INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 – 2023
4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INFLUENZA VACCINES MARKET , BY VACCINE TYPE, 2012 - 2023
5.1. Killed or Inactivated Vaccine
5.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Live Vaccine
5.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6. GLOBAL INFLUENZA VACCINES MARKET , BY STRAIN TYPE, 2016-2016 AND FORECAST 2017 - 2023
6.1. Trivalent Influenza Vaccine
6.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.2. Quadrivaleant Influenza Vaccine
6.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY FORMULATION TYPE, 2012-2016 AND FORECAST 2017 - 2023
7.1. Injections
7.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Nasal Sprays
7.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
8. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012-2016 AND FORECAST 2017 - 2023
8.1. Government Immunization programmes
8.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Non Governmental Organizations (NGOs)
8.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Hospitals
8.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Clinics
8.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Clinics
8.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
9. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY REGION, 2012-2016 AND FORECAST 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East & Africa
9.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel and Region, 2012-2016 and Forecast 2017 – 2023
10. NORTH AMERICA INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
10.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Killed or Inactivated Vaccine
10.1.1.2. Live Vaccine
10.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Trivalent Influenza Vaccine
10.1.2.2. Quadrivaleant Influenza Vaccine
10.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.3.1. Injections
10.1.3.2. Nasal Sprays
10.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.4.1. Government Immunization programmes
10.1.4.2. Non Governmental Organizations (NGOs)
10.1.4.3. Hospitals
10.1.4.4. Clinics
10.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.5.1. U.S
10.1.5.2. Canada
10.1.6. North America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
10.1.7. North America Influenza Vaccines market Dynamics - Trends
11. EUROPE INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
11.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Killed or Inactivated Vaccine
11.1.1.2. Live Vaccine
11.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2 Trivalent Influenza Vaccine
11.1.2.1. Quadrivaleant Influenza Vaccine
11.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.3.1. Injections
11.1.3.2. Nasal Sprays
11.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Government Immunization programmes
11.1.4.2. Non Governmental Organizations (NGOs)
11.1.4.3. Hospitals
11.1.4.4. Clinics
11.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Italy
11.1.5.5. Spain
11.1.5.6. Poland
11.1.5.7. Russia
11.1.5.8. Rest of Europe
11.1.6. Europe Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
11.1.7. Europe Influenza Vaccines market Dynamics - Trends
12. ASIA-PACIFIC INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
12.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Killed or Inactivated Vaccine
12.1.1.2. Live Vaccine
12.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Trivalent Influenza Vaccine
12.1.2.2. Quadrivaleant Influenza Vaccine
12.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Injections
12.1.3.2. Nasal Sprays
12.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.4.1. Government Immunization programmes
12.1.4.2. Non Governmental Organizations (NGOs)
12.1.4.3. Hospitals
12.1.4.4. Clinics
12.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of APAC
12.1.6. Asia-Pacific Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
12.1.7. Asia-Pacific Influenza Vaccines market Dynamics - Trends
13. LATIN AMERICA INFLUENZA VACCINES MARKET ANALYSIS,2012-2016 AND FORECAST 2017 - 2023
13.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Killed or Inactivated Vaccine
13.1.1.2. Live Vaccine
13.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2.1. Trivalent Influenza Vaccine
13.1.2.2. Quadrivaleant Influenza Vaccine
13.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.3.1. Injections
13.1.3.2. Nasal Sprays
13.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Government Immunization programmes
13.1.4.2. Non Governmental Organizations (NGOs)
13.1.4.3. Hospitals
13.1.4.4. Clinics
13.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezula
13.1.5.5. Rest of Latin America
13.1.6. Latin America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
13.1.7. Latin America Influenza Vaccines market Dynamics - Trends
14. MIDDLE EAST & AFRICA INFLUENZA VACCINES MARKET ANALYSIS,2012-2016 AND FORECAST 2017 - 2023
14.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1.1. Killed or Inactivated Vaccine
14.1.1.2. Live Vaccine
14.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.2.1. Trivalent Influenza Vaccine
14.1.2.2. Quadrivaleant Influenza Vaccine
14.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.3.1. Injections
14.1.3.2. Nasal Sprays
14.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.4.1. Government Immunization programmes
14.1.4.2. Non Governmental Organizations (NGOs)
14.1.4.3. Hospitals
14.1.4.4. Clinics
14.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. Middle East & Africa Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
14.1.7. Middle East & Africa Dynamics - Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. GlaxoSmithKline, plc.
15.2.2. Seqirus (CSL Limited)
15.2.3. AstraZeneca
15.2.4. Sanofi
15.2.5. Sinovac Biotech Ltd
15.2.6. Novavax, Inc
15.2.7. DAIICHI SANKYO COMPANY, LIMITED
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL INFLUENZA VACCINES MARKET INTRODUCTION
2.1. Global Influenza Vaccines market – Taxonomy
2.2. Global Influenza Vaccines market –Definitions
2.2.1. Vaccine Type
2.2.2. Strain Type
2.2.3. Formulation Type
2.2.4. Distribution Channel
2.2.5. Region
3. GLOBAL INFLUENZA VACCINES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Influenza Vaccines market Dynamics – Factors Impact Analysis
3.6. Global Influenza Vaccines market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Influenza Vaccines market – Product Innovations
3.8. Competitor Landscape
4. GLOBAL INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 – 2023
4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INFLUENZA VACCINES MARKET , BY VACCINE TYPE, 2012 - 2023
5.1. Killed or Inactivated Vaccine
5.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Live Vaccine
5.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6. GLOBAL INFLUENZA VACCINES MARKET , BY STRAIN TYPE, 2016-2016 AND FORECAST 2017 - 2023
6.1. Trivalent Influenza Vaccine
6.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.2. Quadrivaleant Influenza Vaccine
6.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY FORMULATION TYPE, 2012-2016 AND FORECAST 2017 - 2023
7.1. Injections
7.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Nasal Sprays
7.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
8. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012-2016 AND FORECAST 2017 - 2023
8.1. Government Immunization programmes
8.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Non Governmental Organizations (NGOs)
8.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Hospitals
8.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Clinics
8.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Clinics
8.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
9. GLOBAL INFLUENZA VACCINES MARKET FORECAST, BY REGION, 2012-2016 AND FORECAST 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East & Africa
9.5.1. Market Analysis, 2012-2016 and Forecast, 2012-2016 and Forecast 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel and Region, 2012-2016 and Forecast 2017 – 2023
10. NORTH AMERICA INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
10.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Killed or Inactivated Vaccine
10.1.1.2. Live Vaccine
10.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Trivalent Influenza Vaccine
10.1.2.2. Quadrivaleant Influenza Vaccine
10.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.3.1. Injections
10.1.3.2. Nasal Sprays
10.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.4.1. Government Immunization programmes
10.1.4.2. Non Governmental Organizations (NGOs)
10.1.4.3. Hospitals
10.1.4.4. Clinics
10.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.5.1. U.S
10.1.5.2. Canada
10.1.6. North America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
10.1.7. North America Influenza Vaccines market Dynamics - Trends
11. EUROPE INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
11.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Killed or Inactivated Vaccine
11.1.1.2. Live Vaccine
11.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2 Trivalent Influenza Vaccine
11.1.2.1. Quadrivaleant Influenza Vaccine
11.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.3.1. Injections
11.1.3.2. Nasal Sprays
11.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Government Immunization programmes
11.1.4.2. Non Governmental Organizations (NGOs)
11.1.4.3. Hospitals
11.1.4.4. Clinics
11.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Italy
11.1.5.5. Spain
11.1.5.6. Poland
11.1.5.7. Russia
11.1.5.8. Rest of Europe
11.1.6. Europe Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
11.1.7. Europe Influenza Vaccines market Dynamics - Trends
12. ASIA-PACIFIC INFLUENZA VACCINES MARKET ANALYSIS, 2012-2016 AND FORECAST 2017 - 2023
12.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Killed or Inactivated Vaccine
12.1.1.2. Live Vaccine
12.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Trivalent Influenza Vaccine
12.1.2.2. Quadrivaleant Influenza Vaccine
12.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Injections
12.1.3.2. Nasal Sprays
12.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.4.1. Government Immunization programmes
12.1.4.2. Non Governmental Organizations (NGOs)
12.1.4.3. Hospitals
12.1.4.4. Clinics
12.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of APAC
12.1.6. Asia-Pacific Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
12.1.7. Asia-Pacific Influenza Vaccines market Dynamics - Trends
13. LATIN AMERICA INFLUENZA VACCINES MARKET ANALYSIS,2012-2016 AND FORECAST 2017 - 2023
13.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Killed or Inactivated Vaccine
13.1.1.2. Live Vaccine
13.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2.1. Trivalent Influenza Vaccine
13.1.2.2. Quadrivaleant Influenza Vaccine
13.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.3.1. Injections
13.1.3.2. Nasal Sprays
13.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Government Immunization programmes
13.1.4.2. Non Governmental Organizations (NGOs)
13.1.4.3. Hospitals
13.1.4.4. Clinics
13.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezula
13.1.5.5. Rest of Latin America
13.1.6. Latin America Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
13.1.7. Latin America Influenza Vaccines market Dynamics - Trends
14. MIDDLE EAST & AFRICA INFLUENZA VACCINES MARKET ANALYSIS,2012-2016 AND FORECAST 2017 - 2023
14.1.1.Vaccine Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1.1. Killed or Inactivated Vaccine
14.1.1.2. Live Vaccine
14.1.2.Strain Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.2.1. Trivalent Influenza Vaccine
14.1.2.2. Quadrivaleant Influenza Vaccine
14.1.3.Formulation Type Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.3.1. Injections
14.1.3.2. Nasal Sprays
14.1.4.Distribution Channel Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.4.1. Government Immunization programmes
14.1.4.2. Non Governmental Organizations (NGOs)
14.1.4.3. Hospitals
14.1.4.4. Clinics
14.1.5. Country Analysis Forecast (2012-2016 and Forecast 2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. Middle East & Africa Influenza Vaccines market - Opportunity Analysis Index, By Vaccine Type, Strain Type, Formulation Type, Distribution Channel, and Country, 2012-2016 and Forecast 2017 – 2023
14.1.7. Middle East & Africa Dynamics - Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. GlaxoSmithKline, plc.
15.2.2. Seqirus (CSL Limited)
15.2.3. AstraZeneca
15.2.4. Sanofi
15.2.5. Sinovac Biotech Ltd
15.2.6. Novavax, Inc
15.2.7. DAIICHI SANKYO COMPANY, LIMITED
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
